[Edaily Reporter Kwon Oh Seok ] Shaperon Inc.(378800), a developer of innovative immunotherapy drugs, announced on the 2nd that it has completed the acquisition of the rapidly growing beauty company Niztech and held a launch ceremony to mark the merger of the two companies.

By incorporating NezTech—which recently recorded an annual growth rate of 200%—as a subsidiary, Shaperon Inc. plans to establish a foundation for sustainable growth by combining its proprietary technologies in the anti-inflammatory and anti-aging fields with NezTech’s brand, distribution, and marketing capabilities. Through this acquisition, the company aims to diversify its business portfolio by expanding into beauty devices and skincare—in addition to its research and development focused on innovative new drugs—and to strengthen its foundation for stable cash generation.
Executives and employees from both companies attended the launch ceremony, and an organizational restructuring was carried out to facilitate integrated operations. Kim Do-seon, Executive Vice President of Shaperon Inc.—who has built up commercialization expertise by holding various key management and business roles at GC Biopharma Corp.—has been appointed as Co-CEO of NezTech and will oversee all aspects of business management. Following the acquisition, Executive Vice President Kim plans to accelerate the transformation toward a “profitable business structure” by streamlining management systems, maximizing synergies, and implementing overseas expansion strategies.
CEO Jeon Sang-yeon, who previously led NezTech, has driven the company’s growth since its founding in 2020 by rapidly expanding its online and offline distribution channels, including corporate welfare malls, Electronic Land, Olive Young, and Kakao Gift. Following its incorporation in 2023, the company achieved average annual growth of over 200%—driven by its healthcare brand “Hugrab” and skincare brand “Vude”—reaching 17 billion won in revenue; it currently maintains annual revenue of around 20 billion won.
Based on his experience in brand launches, channel development, and influencer marketing, CEO Jeon will continue to oversee the sales and marketing divisions, working to strengthen the company’s domestic competitiveness and expand overseas sales channels by leveraging K-Beauty.
Through this acquisition, Shaperon Inc. expects a range of benefits, including enhanced financial stability, accelerated commercialization of biotechnology, and expansion into overseas markets. NezTech’s stable revenue is expected to be reflected in Shaperon Inc.’s consolidated financial results, thereby reducing concerns about financial risk and contributing to the steady securing of funds necessary for R&D on its core pipeline as well as global clinical trials and business development.
Shaperon Inc. plans to accelerate the commercialization of science-based premium products by integrating its anti-inflammatory and anti-aging technologies—accumulated over 20 years—with NezTech’s product portfolio and sales channels; the company has already registered five proprietary cosmetic ingredients in the International Cosmetic Ingredient Dictionary (ICID).
NeedsTech will serve as a “commercial platform” that connects Shaperon Inc.’s anti-inflammatory and anti-aging technologies to the actual market. The vision is that while Shaperon Inc. provides scientific validity and core technologies for the enhancement of its functional product lineup and the development of new brands, NeedsTech will translate these into consumer-friendly brand, product, and channel strategies, thereby creating a virtuous cycle between science and sales.
Furthermore, by leveraging the networks of its U.S. subsidiary, Hudson Therapeutics, and its Hong Kong subsidiary, NizTech plans to establish a global revenue model that simultaneously promotes the transfer of new drug technologies and the sale of beauty products in the North American and Asian markets.
In the global beauty market, growth models that combine biotechnology with distribution and marketing capabilities are gaining attention. L’Oréal’s acquisition of CeraVe and AMOREPACIFIC CORPORATION’s integration of COSRX as a subsidiary are cited as examples of achieving high profitability by combining technology-based product capabilities with global sales and distribution networks. In line with this trend, Shaperon Inc. plans to implement a bio-beauty growth model that excels in both science and sales by seamlessly integrating its core anti-inflammatory and anti-aging technologies with NezTech’s beauty business sales network.
Kim Do-seon, Vice President of Shaperon Inc. and Co-CEO of NezTech, and Co-CEO Jeon Sang-yeon stated, “This integrated launch marks the starting point for building a ‘highly profitable’ bio-beauty growth engine by combining Shaperon Inc.’s anti-inflammatory and anti-aging technologies, accumulated over 20 years, with NezTech’s beauty commercialization capabilities.” “We will move swiftly to organically integrate the scientific and sales strengths of both companies, enabling NezTech to achieve exponential growth in domestic and international markets while allowing Shaperon Inc. to leap forward as a global bio-healthcare company,” they added.